Kura Oncology, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Kura Oncology is a clinical-stage biopharmaceutical company developing targeted small-molecule therapies for genetically defined solid tumors and blood cancers. The filing covers the quarter ended March 31, 2016, and was filed May 11, 2016. Kura had no approved products and no product-sales revenue.
- Lead program: tipifarnib, being evaluated in Phase 2 trials for HRAS-mutated solid tumors and peripheral T-cell lymphoma, with additional hematologic cancer studies planned or initiated.
- Pipeline: KO-947, an ERK inhibitor in preclinical development, and a menin-MLL program in lead optimization.
- Common stock outstanding as of May 6, 2016: 21.4 million shares.
Financial Results and Liquidity
| Metric | Three Months Ended March 31, 2016 | Three Months Ended March 31, 2015 |
|---|---|---|
| Research and development expense | $4.649 million | $3.628 million |
| General and administrative expense | $2.391 million | $1.060 million |
| Total operating expenses | $7.040 million | $4.688 million |
| Other income, net | $0.414 million | $0.212 million |
| Net loss | $6.626 million | $4.476 million |
| Basic and diluted loss per share | $0.36 | $1.41 |
| Net cash used in operating activities | $7.314 million | $4.123 million |
- Revenue: no product revenue. Other income included $300,000 of related-party management fee income and $114,000 of interest income.
- Cash, cash equivalents and short-term investments totaled $78.5 million at March 31, 2016, including $16.3 million of cash and cash equivalents and $62.1 million of short-term investments.
- Accumulated deficit was $32.9 million. Total assets were $80.4 million and total liabilities were $4.3 million.
- The filing does not provide a meaningful operating or net margin because the company had no product revenue and remained loss-making.
- Investing cash flow was $8.2 million, principally reflecting $12.2 million of marketable-security maturities, partly offset by $4.0 million of purchases.
- No financing cash flow occurred in the quarter; the prior-year period included $56.6 million of financing proceeds, primarily from common stock and convertible notes.
Material Changes Versus the Prior Comparable Period
- Net loss increased by $2.2 million, or approximately 48%, driven by higher development and public-company costs.
- Research and development expense increased $1.0 million, or 28%, primarily from higher outsourced research, personnel and clinical-development costs, partly offset by lower license fees and share-based compensation.
- General and administrative expense increased $1.3 million, or 126%, mainly due to patent costs, professional and consulting fees, personnel costs and corporate expenses associated with operating as a public company.
- Operating cash use increased $3.2 million to $7.3 million.
- Loss per share improved to $0.36 from $1.41 because the weighted-average share count increased substantially following prior financing activity, despite the higher absolute net loss.
- Short-term investments declined by $8.2 million from December 31, 2015, while cash and cash equivalents increased by $0.9 million.
Guidance, Outlook, Risks and Unusual Items
- Management expected existing cash, investments and the subsequently obtained debt financing to fund current operations into 2018, but stated that substantial additional financing will be required.
- Management expected significant increases in research and development and general and administrative spending during the remainder of 2016.
- The company anticipated submitting an IND for KO-947 in the second quarter of 2016 and commencing a Phase 1 trial in the second half of 2016. It also planned additional tipifarnib studies, including a CMML Phase 2 trial in the second half of 2016.
- On April 27, 2016, after quarter-end, Kura borrowed $7.5 million under a term-loan facility providing for up to $20.0 million. Up to an additional $12.5 million could become available subject to the stated conditions, including advancement of KO-947 into Phase 1.
- The term loans mature November 1, 2020, bear interest at the greater of 7.75% or prime plus 4.25%, and include a 7.5% final payment, prepayment charges and customary restrictive covenants. Warrants to purchase 67,976 shares were issued at an exercise price of $3.31 per share.
- Key risks include continued losses, dependence on additional capital, clinical-trial delays or failure, patient-enrollment challenges for genetically defined cancers, regulatory non-approval, manufacturing and third-party dependence, intellectual-property limitations, and potential dilution or debt-related restrictions.
- Tipifarnib composition-of-matter patents were expected to expire in 2016 in the United States and Europe, increasing reliance on other intellectual-property and regulatory-exclusivity strategies.
- Related-party transactions included $1.2 million of research and development expense under an agreement with an affiliate and $300,000 of management fee income. No material legal proceedings or off-balance-sheet arrangements were reported.
Important Facts for Investors to Verify
- Whether the stated cash runway into 2018 remains achievable after planned clinical-trial expansion and increasing operating losses.
- The conditions and availability of the additional $12.5 million under the term-loan facility, including the KO-947 Phase 1 requirement and covenant compliance.
- Progress, enrollment and clinical results for tipifarnib trials, particularly the HRAS-mutated solid-tumor and hematologic indications.
- Timing and outcome of the KO-947 IND submission and Phase 1 trial.
- The effect of tipifarnib patent expirations, regulatory exclusivity and potential generic competition.
- Future financing needs, potential equity dilution, debt restrictions and the company’s ability to obtain capital on acceptable terms.